Westminster Health Forum

The future of biosimilars in the UK - innovation, regulation and increasing uptake

Morning, Thursday, 18th October 2018

Congress Centre, 28 Great Russell Street, London WC1B 3LS


This seminar will consider the next steps in the development of biosimilars and their role in the NHS - bringing out latest thinking on potential cost saving, developing commissioning frameworks and encouraging uptake, and regulatory issues.

It takes place as the Government analyses feedback from a consultation on legislation to control the costs of branded health medicines - with proposals looking at including biosimilars within the remit of the payment mechanism and price controls.

Delegates will discuss what measures can be taken to encourage the adoption of biosimilars in light of findings from the Cancer Vanguard - as well as the wider impact of the Life Sciences Industrial Strategy in bringing new biological medicines to the market, and encouraging investment in biosimilar exports and manufacturing.

Discussion will also assess the next steps for the regulation of biosimilars and for responding to new entrants in the market - as the seminar follows the recent guidance from the Department of Health and Social Care on what the planned implementation period for Brexit means for the life science sector.

Further sessions will assess what more might be done to support the uptake of biosimilars in the NHS - including priorities for increasing engagement with clinicians, developing local commissioning frameworks and promoting patient choice.

Guest of Honour

Dr Christian Schneider

Director, National Institute for Biological Standards and Control, Medicines and Healthcare products Regulatory Agency

Guest of Honour

Dr Christian Schneider

Director, National Institute for Biological Standards and Control, Medicines and Healthcare Products Regulatory Agency

Keynote Speaker

Theo Christie

Theo Christie, Business Development Manager, NIHR Clinical Research Network


Daniel Zeichner MP

Vice-Chair, All-Party Parliamentary Group for Life Sciences

Chris Green MP

Chair, All-Party Parliamentary Group on Medical Research


Julie Wood

Chief Executive, NHS Clinical Commissioners

Dr Alasdair Rankin

Director of Research and Patient Experience, Bloodwise

Marjan Noor

Partner, Allen & Overy

Dr Martin Perry

Consultant Physician & Rheumatologist, NHS Greater Glasgow and Clyde

Dr James Rose

Head of Clinical Innovation Adoption, Oxford Academic Health Science Network

Angela McFarlane

Market Development Director, IQVIA

Jatinder Harchowal

Chief Pharmacist, The Royal Marsden NHS Foundation Trust

Kavya Gopal

Head of Specialty, Sandoz and Chair, British Biosimilars Association